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Abstract
The enzyme pantothenate synthetase, PanC, is an attractive drug target in Mycobacterium tuberculosis. It is essential for the
in vitro growth of M. tuberculosis and for survival of the bacteria in the mouse model of infection. PanC is absent from
mammals. We developed an enzyme-based assay to identify inhibitors of PanC, optimized it for high-throughput screening,
and tested a large and diverse library of compounds for activity. Two compounds belonging to the same chemical class of
3-biphenyl-4- cyanopyrrole-2-carboxylic acids had activity against the purified recombinant protein, and also inhibited
growth of live M. tuberculosis in manner consistent with PanC inhibition. Thus we have identified a new class of PanC
inhibitors with whole cell activity that can be further developed.
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Introduction
Nearly one third of the human population is infected with
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB)
[1]. Despite the existence of approved drug regimens against TB, it
continues to claim approximately 1.4 million lives every year [1],
and the emergence of increasingly drug resistant strains has made
the need for improved therapies more urgent.
A hallmark of M. tuberculosis is its lipid-rich cell wall, which is an
essential element of intracellular survival and pathogenicity, and is
also thought to contribute to the difficulty of effectively delivering
antimicrobial agents into the cell. The significance of this lipid-rich
cell wall is underscored by the large number of genes (,250)
encoding enzymes in fatty acid metabolism present in the M.
tuberculosis genome [2], making this pathway a promising target for
new antibacterial drug discovery. Indeed, several anti-tubercular
agents are known to inhibit cell wall biosynthesis.
The panC gene encodes the enzyme pantothenate synthetase (PS
or PanC), necessary for the production of pantothenate (vitamin
B5) in bacteria. Pantothenate is a key precursor for the
biosynthesis of coenzyme A (CoA) and acyl carrier protein
(ACP), critical components of fatty acid synthesis. The gene
encoding PanC is essential for optimal growth in vitro [3], and
when genetically disrupted in M. tuberculosis, the resulting strain is
auxotrophic, requiring pantothenate supplementation for growth
[4,5]. Additionally, pathogenicity is severely attenuated in the
pantothenate auxotroph [6]. PanC is absent in mammals, who
scavenge pantothenate from their diet using pantothenate
permease [7,8], of which there is no homolog in M. tuberculosis.
This suggests the potential for developing drugs that do not have
cross-reactive toxicity to homologs in the host, and makes PanC an
attractive drug target in M. tuberculosis.
PanC catalyzes the ATP-dependent condensation of pantoate
and b-alanine to form pantothenate, simultaneously releasing
AMP and pyrophosphate [9]. Previously described assays of PanC
activity coupled AMP production to an enzyme cascade that
results in the oxidation of NADH to NAD+ in reactions catalyzed
by myokinase, pyruvate kinase and lactate dehydrogenase [9]. An
enzyme-based screen of M. tuberculosis PanC (PanCMTB) against a
library of 4080 compounds identified a weak in vitro inhibitor with
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no observable whole cell activity [10]. However, because this assay
relied on a kinetic measurement, and because absorbance
measurements of NADH at 340 nM are often complicated by
auto-fluorescence in a compound library, we chose to adapt this
assay for high throughput screening. The kinetic assay was
modified to generate a fluorescent signal that can be measured as a
single time-point (end point assay). We used this assay to conduct a
high-throughput screen against a large and diverse compound
library, and identified several novel inhibitors of PanCMTB, some
of which are active against live M. tuberculosis.
Materials and Methods
Chemicals
Chemicals were obtained from Sigma Aldrich, unless otherwise
noted. Pantoate was synthesized as previously described [9].
Myokinase (M3003), pyruvate kinase (P1506), and L-lactic
dehydrogenase (L2500) all isolated from rabbit muscle, were
purchased from Sigma Aldrich.
Isolation and purification of recombinant PanCMTB
(Rv3602c)
An Escherichia coli expression vector (pET28b+) encoding
PanCMTB with an amino-terminal 6X-Histidine tag (Dr. Courtney
Aldrich, University of Minnesota) was transformed into E. coli
BL21(DE3), grown to mid-log phase and induced with 0.2 mM
IPTG at 18uC for 16 hours. A cell lysate was prepared by
treatment with lysozyme and sonication; the cleared lysate was
applied first to a nickel column to isolate His-tagged proteins,
followed by an additional step of purification by size exclusion
chromatography (HisTrap and Sepharose 200, Amersham).
PanCMTB, purified to apparent homogeneity by SDS-PAGE,
was concentrated to 2–5 mg/mL in 50 mM HEPES, 50 mM
NaCl, 5 mM MgCl2 and 5% glycerol, flash frozen and stored at
280uC until use.
Low-throughput assay for PanCMTB activity- kinetic NADH
depletion
The activity of recombinant PanCMTB was measured, as
previously described [9]. Briefly, compounds or carrier DMSO
alone were incubated with PanCMTB, the coupling enzymes, and
their reagents for five minutes. The reaction was then initiated by
addition of the PanCMTB substrates, pantoate and b-alanine. The
reaction was conducted in wells of a black clear-bottomed
microplate containing a final volume of 40 mL per well. The final
concentrations were 0.4 mM NADH, 10 mM ATP, 1 mM
pantoate, 5 mM b-alanine, 1 mM phosphoenol pyruvate (PEP-
K), 10 mM MgCl2, 2% DMSO, 1 mg/mL of PanC, and 18 U/
mL each of myokinase, pyruvate kinase and lactate dehydrogenase
in 100 mM HEPES pH 7.8. The plate was immediately trans-
ferred to a SpectraMax micro-plate reader and the rate of NADH
depletion was monitored by measuring the absorbance at 340 nm
every 20 s for a total of 20 min.
High-throughput assay for PanCMTB activity- single-
timepoint fluorescence
The assay was run using a Beckman Coulter Core robotic
system. Key components included an ORCA arm, Multimek,
Nanoscreen, Victor 2, custom deck chiller and custom plate
shuttles. The automated components were controlled and
scheduled using SAMI software. Assay results were determined
using custom software and managed with Collaborative Drug
Figure 1. Single-time point fluorescence assay for PanC. A) Reaction schematic. Upper panel shows the reaction catalyzed by PanC and the
enzyme cascade that is initiated by the reaction product AMP resulting in bNADH oxidation. Lower panel shows the final bNADH dependent
fluorescence generating reaction that is coupled to the PanC-initiated enzyme cascade. B) Low-throughput assay: kinetic reaction monitoring the
rate of bNADH oxidation. C) High-throughput assay: fluorescent resorufin signal generated by residual bNADH following the PanC initiated enzyme
cascade. D) Fluorescence generated with varied bNADH in solution using the same conditions as in (B).
doi:10.1371/journal.pone.0072786.g001
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Discovery’s (CDD) Laboratory Information Management System
(LIMS).
The assay is shown in Figure 1A. The kinetic NADH depletion
assay was initiated as described above. After 30 minutes 10 mL of
solution containing fluorescent reagents was added to each well.
The final 50 mL reaction contained 12.5 U/mL of diaphorase and
5 mM resazurin. After thorough mixing, the plate was transferred
to a micro-plate reader and the level of resulting NADH-
dependent resorufin determined by measuring fluorescence
(excitation and emission filters set at 560 nM and 590 nM,
respectively).
Preparation of compound plates for HTS and for CRC
HTS library sets of individual compounds were plated at 1 mM
- diluted first into HEPES and finally into the assay for a final assay
concentration (FAC) of 20 mM. For concentration response curves
(CRCs), the compounds were plated in single wells at 10 mM and
diluted 3-fold across 9 adjacent wells in a row. Serial dilutions were
made in 100% DMSO to ensure accurate concentrations of
compound across the series. This entire plate was then treated in
the same format as the HTS library plates, for FACs ranging from
200 mM- 0.01 mM in 2% DMSO (details provided in Text S1 and
shown in Figure S3).
Analog Retrieval
Analog retrieval from the Lilly collection was performed by
chemical fingerprint similarity search (Tanimoto similarity thresh-
old of 0.8). The molecular composite fingerprints used for this
study consisted of four components. First, 2048 bits were derived
from linear paths similar to Daylight fingerprints, then 160 bits
that had their origins in the MACCS keys. A further 160 bits were
derived from the second bit vector, but where bits were set only
when repeated features were found. In addition, 8 molecular
properties were added (atom count, size of largest ring, number of
rings, number of ring atoms, number of aromatic atoms, number
of fused ring atoms, number of heteroatoms) [11,12].
Strains
M. tuberculosis H37Rv (ATCC 27294) was used as the parent
strain in all experiments (also referred to by the abbreviation RvS).
PanC-TetONM, a strain in which panC (Rv3602c) is under the
conditional expression of a tetracycline-inducible promoter [5] was
used in this study. The strain was maintained and cultured in the
presence of 50 mg/mL of hygromycin, 20 mg/mL kanamycin and
50 mg/mL pantothenate supplement (vitamin B5), unless other-
wise specified.
M. tuberculosis viability assays
M. tuberculosis strains RvS and PanC-TetONM were grown to
log phase (OD600,0.3), diluted to a final theoretical OD600 of
0.002 and dispensed into a 96-well round-bottom plate (Corning,
Acton, MA) in a final volume of 180 mL. To these cells 20 mL of
compound diluted in 7H9 and 10% DMSO was added to yield
200 mL (final concentration of 1% DMSO). For each strain,
control wells containing no compound were used as a measure of
100% growth, while wells containing a 1:100 dilution of the
starting culture were used as a measure of 99% inhibition. RvS
was plated in 7H9 containing 0.2% w/v glycerol, 10% v/v OADC
supplement (oleic acid, albumin, D-glucose, catalase; Becton
Dickinson) and 0.05% w/v Tween 80 (7H9-GAT) with 0.5 ng/
mL anhydrotetracycline (ATc). PanC-TetONM was plated in
7H9-GAT with 12.5 mg/mL of hygromycin, 6.25 mg/mL kana-
mycin and 0.5 ng/mL ATc, either in the presence or absence of
50 mg/mL pantothenate. Plates were incubated at 37uC for 6 days,
cells were resuspended by pipetting and 20 mL of the total cell
mixture was used in a Bac-Titer GloTM (Promega, Madison, WI)
assay of cell viability, as per the manufacturer’s instructions.
Luminescence readings were conducted on a FluoStar Omega
plate reader (BMG Lab Tech, Cary, NC). Data from dose-
response experiments was represented as the percent inhibition
compared with the no-drug controls and analyzed with Graphpad
PrismTM (San Diego, CA). The MIC50 for each growth condition
was calculated by fitting the data to a non-linear least-squares
curve.
Cytotoxicity assay
Cytotoxicity was measured against the African green monkey
adult kidney cell line (Vero). Vero cells were plated at 25,000 cells/
mL in black 96-well assay plates pre-populated with compound
dilutions and controls. Cells were incubated in a humidified 5%
CO2 environment at 37uC for 48 h; intracellular ATP levels were
measured using CellTiter-GloHReagent (Promega, Madison, WI)
[13]. Luminescence was measured using a Victor 2 plate reader
and percentage inhibition of growth calculated. Results were
expressed as toxicity concentration (TC50) = concentration of
compound required to inhibit growth by 50%.
Results
Assay description
Recombinant PanCMTB was expressed and purified in E. coli.
We confirmed the enzymatic activity of the purified enzyme using
the kinetic assay [9] (Figure 1B) and then adapted it to be more
amenable to high throughput screening. Rather than a kinetic
measurement of NADH depletion the level of NADH was
determined by the terminal addition of the enzyme diaphorase
and its substrate, resazurin, which is converted into the fluorescent
dye, resorufin, in an NADH-dependent reaction. In this end-point
fluorescence assay the PanCMTB reaction was initiated and then
allowed to proceed, depleting the NADH present in solution. After
a defined incubation time, while the PanCMTB reaction was still
progressing linearly, the diaphorase and resazurin were added,
initiating the reduction of the dye with the remaining NADH. We
titrated the concentrations of diaphorase and resazurin so that the
fluorescent signal developed rapidly and demonstrated linear
proportionality to the amount of NADH present in solution
(Figure 1D). Therefore, the final fluorescence was inversely
proportional to the activity of PanCMTB (Figure 1C).
In a set of representative experiments, the reaction conducted
with varying levels of PanCMTB resulted in varied rates of NADH
depletion (Figure 1B). The reactions were then coupled to the
fluorescence reagents, and levels of the resulting NADH-depen-
dent resorufin measured (Figure 1C). When no PanCMTB was
present the fluorescence signal was high. When increasing
amounts of PanCMTB were present, the rate of AMP production
rose, causing progressive depletion of NADH in the initial
reaction, ultimately resulting in a drop in the final fluorescence
(Figure 1C). In addition to determining assay conditions under
which the fluorescence readout was proportional to levels of active
PanCMTB, we confirmed that the assay was also proportionately
sensitive to varied levels of the substrate, pantoate, by holding the
concentration of recombinant PanCMTB constant, but varying the
concentrations of pantoate (data not shown). After successfully
coupling the kinetic NADH depletion assay to an end-point
fluorescent reaction, we optimized it for translation to an HTS
format and tested the robustness of this system to confirm that it
was HTS-compatible.
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Development and validation for HTS compatibility
All validation steps and the final HTS were performed in 384-
well plates using a 320 array of compounds (Figure 2A) with the
two outside columns on each side of the plate (columns 1, 2, 23
and 24) reserved for appropriate controls, and the central 20
columns for 320 wells of test compounds. As a negative control
reaction, to mimic 100% inhibition, we compared reactions
conducted without substrate or without enzyme; there was no
significant difference between the two. The substrate-free negative
control reaction was simpler to incorporate into the HTS flow
deck layout/geometry and was chosen as the ‘‘maximum
inhibition’’ control. Two different concentrations of control
inhibitor (nafronyl oxalate) that consistently displayed ,50%
and ,80% inhibition of the reaction were placed in the two outer
most columns of the plate (1 and 24). The positive controls (full
reactions with no inhibition) and negative controls were contained
in columns 2 and 23, respectively, in order to minimize any chance
of edge-effects. Each of the four controls was performed in 16 wells
per plate, a number of replicates that provided powerful statistical
evaluation. We confirmed that the reagents were stable in the
assay conditions (Text S1). In order to minimize the auto-
oxidation of NADH we used a custom-chilling unit maintained at
4uC as a reservoir for NADH-containing solutions. All solutions
were freshly prepared every four hours.
Various parameters in the assay were developed and optimized,
summarized below and detailed in the Text S1). We created
individual programs for each of the separate liquid additions in
this assay. This included optimization of the liquid handling steps
for each of the robots; adjusting the heights, aspiration and
dispensation speeds as well as other protocol details including
mixing reagents (Figure S4); and washing of tips. Synchronizing
the NADH depletion initiation and the fluorescence generating
reaction as tightly as possible reduced variation across a plate.
Finally we used the appropriate optic filters in the Victor2 Wallac
plate-reader that allowed us to obtain optimal excitation and
emission of resorufin with minimal spectral overlap from the light
source, and minimal auto fluorescence (details in Text S1).
Validation of HTS compatibility was performed based on
NCGC guidelines [14] using the 320-array format described
earlier (Figure S1). After confirming low variation of signal across
Figure 2. Design and implementation of HTS campaign. A) Plate layout for 320-array with four sets of controls (n = 16 for each) in columns 1,
2, 23, and 24. B) Results from Blank Plate Validation using DMSO alone in all 320 assay wells.
doi:10.1371/journal.pone.0072786.g002
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the 320 test wells with uninhibited reactions (Figure 2B, %
CV = 2.27) we tested three different concentrations of the control
inhibitor, nafronyl oxalate. (2.5 mM, 250 mM and 750 mM) that
resulted in a minimum (min), medium (mid) and maximum (max)
level of inhibition. Two replicate plates of each, were run on a
single day, and repeated on three separate days (for a total of six
plates). The resulting % CV across each of the plates ranged from
3.7%–12.9% (Figure S1), acceptable for continuing with the HTS.
We performed a final validation of HTS-compatibility by testing a
small subset of the LISSP4 library. Three compound plates, each
containing 320 compounds, were randomly selected and each was
assayed at 5 mM, 10 mM and 20 mM (Figure S2). In addition a 10th
plate with no compounds in the 320-array was run alongside these
plates. We found that 20 mM showed good levels of inhibition with
low background signal. We also saw dose-dependent inhibition
from one well, indicating that the pilot screen was successful
(Figure S2). The Z9 factor [15] for the controls of each of the three
plates tested at 20 mM were 0.803, 0.804 and 0.824 confirming
that the assay performance was robust at this concentration.
Screening LISSP4 Library (27.5 K compounds) and
Diversity Library (62.6 K compounds)
Having determined that the fluorescently coupled end-point
assay was compatible with high-throughput screening, we
proceeded to screen two large compound libraries derived from
the Eli Lilly screening collection of .800 K physical samples. The
library can be subdivided into a set representing compounds
previously identified as actives against human targets (LISSP4 –
Lilly Strategic Screening Paradigm 4th iteration) and a set of
generally diverse compounds (Diversity 4th iteration) not identified
as actives at the time of library construction. LISSP4 contains a
representative set of 27582 molecules from active (typically
,1 mM) classes of druggable human proteins: proteases, kinases,
phosphodiesterases (PDE), GPCRs, nuclear hormone receptors,
transporters, etc. Diversity4 contains 62651 molecules represen-
tative of compounds from the remainder of the library. The sets
were created in November 2008.
The LISSP4 library (27,582 compounds) was screened at a final
assay concentration of 20 mM (Figure 3A). Two compounds which
showed maximum inhibition were identified as promiscuous
inhibitors and were removed from further studies. One compound
inhibited 41.1% and eleven compounds inhibited .20%. Many
compounds showed modest inhibition (10–20%). Although these
had relatively low inhibition in the primary assay a subset of these
were considered significant because they inhibited .3 standard
deviations away from the mean inhibition across that particular
plate.
Although the results from the LISSP4 library confirmed that the
assay could identify inhibitors of PanC activity, this library yielded
a relatively low hit rate. Therefore, we decided to screen a more
diverse compound set, the Diversity library (62,651 compounds) at
20 mM (Figure 3A). Hits were selected as those with inhibition
.15% and at least 3 standard deviations higher than the
background within that plate. There were more than 180 hit
compounds including 6 at .40% and 3 at .60% inhibition. In
total there were 222 primary hits from both libraries.
Confirmation of PanCMTB inhibitory activity
We confirmed our primary hits using two assays. The first was a
counter-screen to identify compounds whose activity is due to
inhibition of one of the coupling enzymes in the reaction. The
second was to run concentration response curves (CRCs).
In addition to the 222 primary hits, the seven most potent
primary hits were used as seeds for analog retrieval from the Lilly
collection. These seven primary hits comprised 5 distinct classes of
compounds; three compounds belonged to the same class. Analog
retrieval was performed by chemical fingerprint similarity search
and supplemented by substructure searches of identified Med-
Chem Studio scaffold (C2) (Simulation Plus Inc.). This resulted in
an additional 78 compounds that were assayed. Of the 300
compounds run against the secondary assays 27 compounds were
positive in counter-screen (.10% inhibition), indicating that they
targeted one or more of the coupling enzymes in the assay. They
were eliminated from further analyses.
The remaining 273 compounds were tested in CRCs against
PanCMTB. Compounds which were active in CRCs (below
200 mM) were grouped into classes using MedChem Studio
scaffold clustering; one class of particular interest was identified.
This class contained three active compounds from the primary
screen and two analogs retrieved by similarity searches. The two
analogs (compounds 1 and 2) had EC50 of 1.8 +/21.1 mM and
4.0+/21.1 mM respectively (Figure 3B and C). Compounds of this
class did not inhibit the counter screen, and showed dose-
dependent inhibition of the PanCMTB. The most potent of the four
primary hits from this class inhibited PanC in the HTS assay by
71.6% at 20 mM. Tanimoto similarity between the two exempli-
fied hits (1 vs. 2) in the fingerprint used in this work space was
0.81.
Characterization of biochemical enzyme inhibition
We used the low-throughput continuous PanCMTB enzyme
assay to determine the mode of inhibition, holding all reagents
constant but varying a single substrate. Reaction rates were
measured as the rate of NADH oxidation and the data were fitted
to nonlinear regressions with GraphPad Prism to generate
Michaelis-Menten plots (Figures 4A and B). In addition, inhibition
constants were determined by nonlinear regression analyses using
the general equation of mixed inhibition in GraphPad PrismTM,
where the resulting parameter ‘‘a’’ determines the mode of
inhibition [16]. Both compounds showed non-linear fits closer to
competitive inhibition with respect to the substrate pantoate,
generating a= 128 and a= 78 for 1 and 2, respectively. Ki
inhibition constants with respect to pantoate were 174+/220 nM
for 1 and 297+/237 nM for 2.
Whole-cell activity against M. tuberculosis
The compounds were tested for growth inhibitory activity
against wild-type M. tuberculosis by monitoring ATP levels in
cultures exposed to compounds. In each growth condition,
bacteria grown in the absence of drug were used as a control
reflecting 100% growth. We found that both compounds 1 and 2
were active against live M. tuberculosis, with MIC50 values of
115 mM and 54 mM respectively (Figure 5). Further, we wanted to
ascertain the degree to which this activity could be attributed to
the specific inhibition of PanCMTB in whole cells. To do this, we
tested the activity of compounds against a conditional PanC-
knockdown strain (PanC Tet-ONM) in which PanC expression is
held under the control of a tetracycline-inducible promoter; in the
presence of low concentrations of tetracycline panC expression is
dramatically reduced [5] and growth is partially attenuated. We
used these conditions to maintain growth, while still having
artificially lowered PanC levels, making the cell line more sensitive
to PanC-mediated inhibition. We found that under lowered panC
expression the MIC50 of both 1 and 2 dropped about two-fold
(Figure 5). The MIC50 of 1 was reduced from 115 mM in wild-type
to 69 mM in the PanC under-expressor strain. Similarly 2 was
more potent against the PanC under-expressor strain with an
MIC50 of 24 mM compared to 54 mM in the wild-type. This
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suggested that the growth defect is linked to PanC-mediated
inhibition. In the presence of higher tetracycline levels panC is
induced in the PanC Tet-ONM strain but this only partially
alleviates the growth defect achieving<80% of wild-type growth.
However, with supplemental pantothenate the pressure caused by
the PanC deficiency is relieved and growth is restored to wild-type
levels [5]. Therefore to confirm that the hypersensitivity to the
PanC inhibitors was not due simply to the attenuated growth, the
compounds were also tested against PanC Tet-ONM grown in the
presence of pantothenate. As expected, the increased sensitivity
was abolished when pantothenate was included in the growth
medium, with 1 and 2 displaying MIC50 values similar to those in
wild type RvS (111 and 53 mM, respectively; Figure 5).
The two compounds were tested for cytotoxicity against the
Vero cell line; both showed some toxicity with TC50 of 70 mM for
compound 1 and 96 mM for compound 2. We also tested for
Figure 3. Screening results. A) Activity of compounds from LISSP4 (grey) and Diversity (black) libraries shown as percent inhibition against
PanCMTB. B) Concentration response curves (CRCs) for two representative hits and nafronyl oxalate. C) Structures of compound 1 and 2.
doi:10.1371/journal.pone.0072786.g003
Figure 4. Biochemical characterization of Class 1 compounds. Michaelis-Menten plots with varied concentrations of pantoate and A)
compound 1 and B) compound 2. Graphpad Prism was used to fit the data to nonlinear regressions.
doi:10.1371/journal.pone.0072786.g004
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toxicity against HeLa cells, where the toxicity was less pro-
nounced, with average TC50 values of 179 mM and 111 mM
respectively.
Discussion
Several inhibitors of PanCMTB have been identified with varied
potency against the enzyme target. A high-throughput screen
conducted by Eisenberg and colleagues identified nafronyl oxalate
as an inhibitor of PanCMTB with an inhibition constant of
,75 mM [10], but with no described activity against live M.
tuberculosis. More potent compounds against PanCMTB have been
developed with the tools of structure-based design from fragment
screens, and substrate and reaction-intermediate analogs [17–19]
[20,21]. The most potent of these displayed nanomolar inhibition
of PanCMTB, but at the most inhibited bacterial growth by ,50%
at 128 mM [19]. Most recently a combination of high throughput
screening and structure-based design yielded an interesting new
inhibitor of PanCMTB [22] whose chemical structure is not related
to the enzyme substrates. Actinomycin D (ActD) was first
identified as an inhibitor of PanCMTB by screening against the
enzyme-based assay [22]. Molecular docking of the ActD
cyclopeptide in the active site of PanCMTB was used to identify
smaller pharmacophores that might bind in a similar fashion. This
revealed one compound with activity against live M. tuberculosis
(MIC99 of ,54 mM) even though it did not show very high
potency in the biochemical assay (IC50 = 22 mM).
We sought to identify compounds with novel chemical
structures that could serve as scaffolds for drug development
targeting PanCMTB. We screened a large and diverse compound
library, and identified a class of compounds with nanomolar
potency against the recombinant purified enzyme. Two com-
pounds were chosen as representative of this class of compounds
and were characterized in further detail. Compounds 1 and 2
showed competitive inhibition with respect to pantoate with Ki of
174.1+/220.0 nM and of 297.1+/237.1 nM respectively.
In order to ascertain whether the growth inhibition against live
M. tuberculosis was caused by on-target activity against PanC, we
utilized a genetically engineered strain of M. tuberculosis in which
the expression of PanC is controlled by a tetracycline inducible
promoter [5]. This promoter-replacement strategy has been
previously used to regulate the expression of target genes in M.
tuberculosis [23]. Mutants with artificially lowered target expression
should be hyper-sensitized to PanC inhibitors, allowing us to infer
target-specificity [5,24]. Moreover, under these conditions a panel
of known anti-tubercular drugs had no shifted MIC [5] indicating
that the strain is not more susceptible to inhibition of unrelated
pathways, and is specifically sensitized to PanC inhibitors.
Additionally, the sensitivity gained by lowering the target levels
increased our ability to see whole-cell activity of compounds that
would otherwise be too weak to be detectable. Both compounds
were active against M. tuberculosis in an apparently PanC-
dependent manner. The MIC50 values were high (55 and
118 mM), but a PanC under-expressor was more sensitive and
this sensitization was relieved by addition of pantothenate. This
suggested the growth inhibitory properties were, at least, partly
due to PanC-mediated inhibition.
Both compounds 1 and 2 have a 4-cyano-1-methyl-3-(4-
phenylphenyl)pyrrole-2-carboxylic acid core structure. This general
compound class has not been studied in depth as antibacterial
agents and might provide a unique starting point for tuberculosis
drug discovery efforts. These and similar compounds have been
reported as a general class of allosteric modulators of the human
AMPA receptors [25]. These may still be valuable starting scaffolds
whose analogs can be interrogated for improved potency against live
M. tuberculosis and lowered activity against mammalian cells.
Supporting Information
Text S1 Detailed information on tip handling during
HTS, compound plating for concentration response
curves, reagent stability testing, robotics optimization,
and optics for resorufin measurement.
(DOC)
Figure S1 Validation of HTS-compatibility assaying
plates with max, mid, and min concentrations of a
control inhibitor.
(PDF)
Figure S2 Data generated in pilot study from one
compound plate assayed at three different concentra-
tions.
(PDF)
Figure S3 Plate layout for concentration response
curves (CRCs).
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Figure 5. Activity against whole-cell M. tuberculosis. Wild-type MTB (RvS; black circles), PanC conditional knockdown (PanC-TetON; white
circles), and the knockdown supplemented with pantothenate (PanC-TetON+supplement; x) were grown in the presence of varied concentrations of
A) compound 1 or B) compound 2. Results are the average and standard deviation of triplicates. The MIC50 was determined by plotting %inhibition
against compound concentration and fitting to a non-linear curve with Graphpad PrismTM.
doi:10.1371/journal.pone.0072786.g005
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Figure S4 Optimizing well-to-well variation with mixing
of solutions by liquid handling equipment.
(PDF)
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